BioMetals

, Volume 27, Issue 5, pp 1007–1016 | Cite as

Lactoferrin for prevention of neonatal sepsis

  • Christie G. Turin
  • Alonso Zea-Vera
  • Alonso Pezo
  • Karen Cruz
  • Jaime Zegarra
  • Sicilia Bellomo
  • Luis Cam
  • Raul Llanos
  • Anne Castañeda
  • Lourdes Tucto
  • Theresa J. Ochoa
  • NEOLACTO Research Group
Article

Abstract

Preterm neonates are at risk to acquire infections. In addition to the high mortality associated with sepsis, these patients are at risk for long-term disabilities, particularly neurodevelopment impairment. Several interventions have been evaluated to reduce rates of infections in neonates but have not proven efficacy. Lactoferrin (LF), a milk glycoprotein with anti-inflammatory, immunomodulatory and anti-microbial properties, has the potential to prevent infections in young children. We performed a review of current and ongoing clinical trials of LF for prevention of neonatal sepsis, and found eleven registered clinical trials that include more than 6,000 subjects. Few of these trials have finished; despite their small sample size, the preliminary results show a trend towards a positive protective effect of LF on neonatal infections. Larger trials are underway to confirm the findings of these initial studies. This information will help to define LF’s role in clinical settings and, if proven effective, would profoundly affect the treatment of low birth weight neonates as a cost-effective intervention worldwide.

Keywords

Lactoferrin Bovine lactoferrin Recombinant human lactoferrin Neonatal sepsis Prevention Clinical trial 

References

  1. Ammons MC, Copie V (2013) Mini-review: lactoferrin: a bioinspired, anti-biofilm therapeutic. Biofouling 29:443–455PubMedCentralPubMedCrossRefGoogle Scholar
  2. Artym J, Zimecki M, Kruzel ML (2004) Enhanced clearance of Escherichia coli and Staphylococcus aureus in mice treated with cyclophosphamide and lactoferrin. Int Immunopharmacol 4:1149–1157PubMedCrossRefGoogle Scholar
  3. Baker HM, Baker EN (2012) A structural perspective on lactoferrin function. Biochem Cell Biol 90:320–328PubMedCrossRefGoogle Scholar
  4. Camacho-Gonzalez A, Spearman PW, Stoll BJ (2013) Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin N Am 60:367–389CrossRefGoogle Scholar
  5. Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP (2001) Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 281:1140–1150Google Scholar
  6. Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP (2013) Lactoferrin: antimicrobial activity and therapeutic potential. Semin Fetal Neonatal 2013:143–149CrossRefGoogle Scholar
  7. Lee WJ, Farmer JL, Hilty M, Kim YB (1998) The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect Immun 66:1421–1426PubMedCentralPubMedGoogle Scholar
  8. Legrand D (2012) Lactoferrin, a key molecule in immune and inflammatory processes. Biochem Cell Biol 90:252–268PubMedCrossRefGoogle Scholar
  9. Leitch EC, Willcox MD (1999) Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J Med Microbiol 48:867–871PubMedCrossRefGoogle Scholar
  10. Lingappan K, Arunachalam A, Pammi M (2013) Lactoferrin and the newborn: current perspectives. Expert Rev Anti Infect Ther 11:695–707PubMedCrossRefGoogle Scholar
  11. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE et al (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379:2151–2161PubMedCrossRefGoogle Scholar
  12. Manzoni P, Rinaldi M, Cattani S, Pugni L, Romeo MG, Messner H et al (2009) Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA J Am Med Assoc 302:1421–1428CrossRefGoogle Scholar
  13. Manzoni P, Stolfi I, Messner H, Cattani S, Laforgia N, Romeo MG et al (2012) Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 129:116–123PubMedCrossRefGoogle Scholar
  14. Nibbering PH, Ravensbergen E, Welling MM, van Berkel LA, van Berkel PH, Pauwels EK et al (2001) Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria. Infect Immun 69:1469–1476PubMedCentralPubMedCrossRefGoogle Scholar
  15. Ochoa TJ, Cleary TG (2009) Effect of lactoferrin on enteric pathogens. Biochimie 91:30–34PubMedCentralPubMedCrossRefGoogle Scholar
  16. Ochoa TJ, Pezo A, Cruz K, Chea-Woo E, Cleary TG (2012) Clinical studies of lactoferrin in children. Biochem Cell Biol 90:457–467PubMedCrossRefGoogle Scholar
  17. Orsi N (2004) The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 17:189–196PubMedCrossRefGoogle Scholar
  18. Shane AL, Stoll BJ (2013) Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Am J Perinatol 30:131–142PubMedCrossRefGoogle Scholar
  19. Shane AL, Stoll BJ (2014) Neonatal sepsis: progress towards improved outcomes. J Infect 68:S24–S32PubMedCrossRefGoogle Scholar
  20. Sharma S, Kumar P, Betzel C, Singh TP (2001) Structure and function of proteins involved in milk allergies. J Chromatogr B Biomed Sci Appl 756:183–187PubMedCrossRefGoogle Scholar
  21. Sheffield CL, Crippen TL, Poole TL, Beier RC (2012) Destruction of single-species biofilms of Escherichia coli or Klebsiella pneumoniae subsp. pneumoniae by dextranase, lactoferrin, and lysozyme. Int Microbiol Off J Span Soc Microbiol 15:185–189Google Scholar
  22. Singh PK, Parsek MR, Greenberg EP, Welsh MJ (2002) A component of innate immunity prevents bacterial biofilm development. Nature 417:552–555PubMedCrossRefGoogle Scholar
  23. Sun XL, Baker HM, Shewry SC, Jameson GB, Baker EN (1999) Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta Crystallogr D Biol Crystallogr 55:403–407PubMedCrossRefGoogle Scholar
  24. Thaver D, Zaidi AK (2009) Burden of neonatal infections in developing countries: a review of evidence from community-based studies. Pediatr Infect Dis J 28:S3–S9PubMedCrossRefGoogle Scholar
  25. Venkatesh MP, Rong L (2008) Human recombinant lactoferrin acts synergistically with antimicrobials commonly used in neonatal practice against coagulase-negative Staphylococci and Candida albicans causing neonatal sepsis. J Med Microbiol 57:1113–1121PubMedCrossRefGoogle Scholar
  26. Vogel HJ (2012) Lactoferrin, a bird’s eye view. Biochem Cell Biol 90:233–244PubMedCrossRefGoogle Scholar
  27. Watson D, O’Connell Motherway M, Schoterman MH, van Neerven RJ, Nauta A, van Sinderen D (2013) Selective carbohydrate utilization by lactobacilli and bifidobacteria. J Appl Microbiol 114:1132–1146PubMedCrossRefGoogle Scholar
  28. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z (1989) Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 70:697–704PubMedCentralPubMedGoogle Scholar
  29. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA (2005) Hospital-acquired neonatal infections in developing countries. Lancet 365:1175–1188PubMedCrossRefGoogle Scholar
  30. Zhang GH, Mann DM, Tsai CM (1999) Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 67:1353–1358PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Christie G. Turin
    • 1
  • Alonso Zea-Vera
    • 1
  • Alonso Pezo
    • 1
  • Karen Cruz
    • 1
  • Jaime Zegarra
    • 1
    • 2
  • Sicilia Bellomo
    • 1
    • 2
  • Luis Cam
    • 3
  • Raul Llanos
    • 4
  • Anne Castañeda
    • 4
  • Lourdes Tucto
    • 1
  • Theresa J. Ochoa
    • 1
    • 5
  • NEOLACTO Research Group
  1. 1.Department of Pediatrics, Instituto de Medicina Tropical “Alexander von Humboldt”Universidad Peruana Cayetano HerediaSan Martin de Porras, Lima 31Peru
  2. 2.Hospital Nacional Cayetano HerediaLimaPeru
  3. 3.Hospital Nacional Alberto SabogalLimaPeru
  4. 4.Hospital Nacional Guillermo AlmenaraLimaPeru
  5. 5.University of Texas Health Science Center at HoustonHoustonUSA

Personalised recommendations